DIabetes REsearCh on Patient sTratification (DIRECT): GLP-1R Agonists

• Status: Completed
• Trial end date: 2015-12-11
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to collect a cohort of patients treated with GLP-1R Agonists and to assess phenotypic, genetic and genomic biomarkers of glycaemic response to these agents.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Evan Pearson; University of Dundee
• Collaborators: Newcastle-upon-Tyne Hospitals NHS Trust; Oxford University Hospitals NHS Trust; Royal Devon and Exeter NHS Foundation Trust
• Treatments: Exenatide; Liraglutide

Criteria

Inclusion Criteria:

• Patients with Type 2 diabetes where a clinical decision has been made to commence a GLP-1R agonist

• Either:

1. On any combination of oral hypoglycaemic agents

2. On Insulin (+/- oral hypoglycaemic agents)

• HbA1c ≥7.5% (58mmol/mol) and HbA1c < 12% (108mmol/mol)

• White European

• Age ≥ 18 and < 80

Exclusion Criteria:

• Type 1 diabetes

• HbA1c <7.5% (58 mmol/mol)

• HbA1c ≥ 12% (108 mmol/mol)

• Pregnancy or lactation

• Any other significant medical reason for exclusion as determined by the investigator

• Inability to consent

• Participating in a CTIMP during the study period and within 30 days prior to study start.